Phase III study results show patients with chronic non-cancer pain and opioid-induced constipation (OIC) experienced improvements in spontaneous bowel movement frequency and other symptoms of OIC.
Researchers claim that restricting dietary intake of fermentable short-chain carbohydrates improves GI symptoms in patients with IBS.
Switching from oral administration of the non-ergoline dopamine agonist, rotigotine, to a transdermal delivery system may improve gastrointestinal symptoms for patients with Parkinson's disease.
Prescribers of extended-release/long-acting (ER/LA) opioid analgesics are encouraged to participate in continuing medical education (CME) provided by manufacturers of these analgesics, according to an open letter published March 1 by the U.S. Food and Drug Administration.
The goal of IBS management should be to improve overall symptoms, including altered stool frequency and consistency, abdominal pain and discomfort, bloating, and quality of life.